Antidepressants 2 ▲ Public Health Genomics Knowledge Base (v1.2)

Public Health Genomics Knowledge Base (v1.2)

Last Posted: Jan 05, 2017

---

• Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update.
  Kevin Hicks J et al. Clinical pharmacology and therapeutics 2016 Dec
• Pharmacokinetic Pharmacogenetic Prescribing Guidelines for Antidepressants: A Template for Psychiatric Precision Medicine.
  Nassan Malik et al. Mayo Clinic proceedings 2016 Jun
• Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine: study protocol for a pragmatic randomized controlled trial (CYSCEtrial).
  Berm Elizabeth J J et al. Trials 2015 1637
• Cost-effectiveness of combinatorial pharmacogenomic testing for treatment-resistant major depressive disorder patients.
  Hornberger John et al. Am J Manag Care 2015 21(6) e357-65
• MTHFR: Genetic variants, expression analysis and COMT interaction in major depressive disorder.
  Gabriela Nielsen Maria et al. J Affect Disord 2015 Sep 1. 179-86
• The role of GRIK4 gene in treatment-resistant depression.
  Milanesi Elena et al. Genet Res (Camb) 2015 e14
• Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a one year prospective evaluation.
  Winner Joel G et al. Curr Med Res Opin 2015 Jun 18. 1-30
• "Getting off the Bus Closer to Your Destination": Patients' Views about Pharmacogenetic Testing.
  Trinidad Susan Brown et al. Perm J 2015 Jun 1.
• Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis.
  Zhou Xinyu et al. J Clin Psychiatry 2015 Apr (4) e487-98
• Treatment of bipolar depression: making sensible decisions.
  Citrome Leslie et al. CNS Spectr 2014 Dec 4-11; quiz 1-3, 12
• Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.
  Hicks J Kevin et al. Clin. Pharmacol. Ther. 2015 May 13.
• Genome-wide association studies in pharmacogenomics of antidepressants.
  Lin Eugene et al. Pharmacogenomics 2015 Apr (5) 555-66
• Identifying genetic loci associated with antidepressant drug response with drug-gene interaction models in a population-based study.
  Noordam Raymond et al. J Psychiatr Res 2015 Mar 31-7
• RNA expression profiling in depressed patients suggests retinoid-related orphan receptor alpha as a biomarker for antidepressant response.
  Hennings J M et al. Transl Psychiatry 2015 e538
• Serotonin pathway polymorphisms and the treatment of major depressive disorder and anxiety disorders.
  Helton Sarah G et al. Pharmacogenomics 2015 Apr (5) 541-53
• The Efficacies and Toxicities of Antidepressant Drugs in Clinics, Building the Relationship between Chemo-Genetics and Socio-Environments.
  Lu Da-Yong et al. Cent Nerv Syst Agents Med Chem 2015 Apr 28.

more

---

Most Recent Scientific Publications from Weekly Horizon Scans

From Genomics & Health Impact Scan Database

This database includes published scientific literature on evidence-based translation of genomic discoveries into improved health care and disease prevention that have a potential impact on population health.

• Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update.
  Kevin Hicks J et al. Clinical pharmacology and therapeutics 2016 Dec
• Pharmacokinetic Pharmacogenetic Prescribing Guidelines for Antidepressants: A Template for Psychiatric Precision Medicine.
  Nassan Malik et al. Mayo Clinic proceedings 2016 Jun
• Genome-wide association studies in pharmacogenomics of antidepressants.
  Lin Eugene et al. Pharmacogenomics 2015 Apr (5) 555-66
• Is there a role for antidepressant and antipsychotic pharmacogenetics in clinical practice in 2014?
  Mulsant Benoit H et al. Can J Psychiatry 2014 Feb (2) 59-61
• Understanding the pharmacogenetics of selective serotonin reuptake inhibitors.
  Fabbri Chiara et al. Expert Opin Drug Metab Toxicol 2014 Aug (8) 1093-118

more